GSK-690693
As of the edition of 20 October 2026, GSK-690693 is a small molecule: stopped in 2009; acts on AKT1, AKT2 and AKT3 and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2009
- Kind
- Small molecule
- Registered trials
- 2, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PRKACA | cAMP-dependent protein kinase catalytic subunit alpha | P17612 |
| PRKACG | cAMP-dependent protein kinase catalytic subunit gamma | P22612 |
| PRKACB | cAMP-dependent protein kinase catalytic subunit beta | P22694 |
| AKT1 | RAC-alpha serine/threonine-protein kinase | P31749 |
| AKT2 | RAC-beta serine/threonine-protein kinase | P31751 |
| AKT3 | RAC-gamma serine/threonine-protein kinase | Q9Y243 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2007 to now |